U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

Impact · against what's priced in

BioMarin expands the addressable market for PALYNZIQ to adolescents aged 12 and older, potentially increasing long-term revenue growth through a broader patient base. The approval provides a unique therapeutic option for a challenging demographic where dietary adherence is often unsustainable.

BMRN+0.50

No priced-in read yet